Identifying AD during life has become increasingly precise with fluid and neuroimaging biomarkers including cerebrospinal fluid (CSF) and positron emission tomography (PET) measurement of beta‐amyloid (Aβ) and phosphorylated tau (p‐tau). This evidence concerns the gene MAPT and Alzheimer disease.